Trophos launches first study of olesoxime in MS patients
Posted: Thu Mar 14, 2013 5:19 am
A Phase 1b study in RRMS patients is starting in three MS reference centers in France
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announces today the initiation of a phase 1b study of olesoxime in multiple sclerosis (MS) patients as a complementary therapy to their treatment with interferon beta.... Read More - http://www.ms-uk.org/index.cfm/MSnews
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announces today the initiation of a phase 1b study of olesoxime in multiple sclerosis (MS) patients as a complementary therapy to their treatment with interferon beta.... Read More - http://www.ms-uk.org/index.cfm/MSnews